it is worth asking an expert like jonathan van—tam or clive dicks if you want a view on whether we couldallenge trials. my view was, i pushed for the system to go as fast as possible, for them to use human challenge trials. but i was not prepared to go faster than the sites would credibly allow. and when it came to other clinical trials, i do hope that for varied vaccines we can get them through quicker because the platform will have already been approved, and the agreement we made in oxford last week at g7 level will undoubtedly speed up future vaccine production. the reason is at the moment in each country, clinical trials are essentially separate because the design of the data standards can be different in different countries, and therefore you cannot always amalgamate the data, and therefore get the extra power you would need to get a clinically validated result sooner, as soon as you could if the data standards where the same and therefore the data was into operable. this may sound technical but the consequence of that clinical trials charter that we aim to implement rapidly will be